Nativis Voyager Device: Publication of Study in Patients with Recurrent Glioblastoma Announced by Nativis
12/19/18: “We are excited to have this publication accepted by CNS Oncology in conjunction with our internationally recognized clinical trial partners, led by Charles Cobbs, MD and Santosh Kesari, MD PhD,” stated Chris Rivera, Nativis Chief Executive Officer. “The data in this early feasibility study not only suggest that the Nativis Voyager device is safe for the treatment of rGBM, but also that further studies to explore clinical utility are warranted.”
Interim results presented for first-in-human study in first of 2-stage study Nativis, Inc., today announced the release of an abstract on its Nativis Voyager® system for use in patients with recurrent glioblastoma multiforme (rGBM). The abstract will be...
Chris Rivera, Chief Executive Officer of Nativis notes, “We are very excited to welcome Dr. Donna Morgan Murray as Chief Regulatory Officer to Nativis. Dr. Murray’s extensive professional accomplishments and medical background will provide Nativis with a...